BOULDER — MiRagen Therapeutics, which specializes in therapeutics based on small ribonucleic-acid molecules, on Tuesday announced it had inked a research, development and commercialization agreement worth more than $350 million with a company based in France.
MiRagen and Les Laboratoires Servier signed a partnership agreement under which Servier would fund the research, development and commercialization of three drug candidates to treat cardiovascular disease. The agreement includes two of MiRagen’s lead programs and one yet-to-be-determined discovery target.
Partnering with a multibillion-dollar drug developer that has experience and a strong toehold in the cardiovascular industry further validates therapies targeting micro RNAs and allows MiRagen to get its therapies in broader circulation.
The 20-person Boulder company will receive as much as $45 million in upfront payments to support research and development, an increase in staffing and a variety of near- term milestones.
As the therapies make their way through clinical development and commercialization, additional milestones kick in, bringing the potential total cash payment to MiRagen to $352 million.
